NewsNow: AIPAC news | Breaking News & Search 24/7
Track breaking AIPAC headlines on NewsNow: the one-stop shop for AIPAC news
Source: newsnow.co.uk
📰 Randomized Phase News
Page 3 - Randomized Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Randomized Phase. Real-time updates on events, politics, business and more.
Ryan DeMasi, MD: Direct and Indirect Impact of Pain in Rheumatoid Arthritis
Ryan DeMasi, MD, explained the direct and indirect effects of upadacitinib and adalimumab on pain in patients with rheumatoid arthritis.
United States San Diego Ryan Demasi American College Of Rheumatology Indirect Effects Rheumatoid Arthritis
Source: hcplive.com
Randomized Phase 3 Study of First-line Selpercatinib vs Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC: LIBRETTO-431
Expert oncologist Benjamin Levy, MD, shares data from the LIBRETTO-431 trial comparing selpercatinib to chemotherapy plus pembrolizumab in RET fusion-positive NSCLC following ESMO 2023.
Benjamin Levy Randomized Phase First Line Selpercatinib Partnership With Non Small Cell Lung Cancer Lung Cancer
Source: onclive.com
Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy for Patients with Metastatic HR+/HER2– BC: Primary Results from the Randomized Phase III TROPION-Breast01 Trial
Expert oncologist Aditya Bardia, MD, reflects on data from the TROPION-Breast01 trial of dato-DXd versus chemotherapy in metastatic HR+/HER2– breast cancer following ESMO 2023.
Aditya Bardia Datopotamab Deruxtecan Primary Results Randomized Phase Previously Treated Inoperable Metastatic Hormone Receptor Positive
Source: onclive.com
COMING SOON: Dato-DXd vs Docetaxel in Previously Treated Advanced/Metastatic Non–Small Cell Lung Cancer: Results of the Randomized Phase III Study TROPION-Lung01
Aaron Lisberg, MD, provides a look at an upcoming Rapid Readout program looking at the results of the TROPION-Lung01 study investigating Dato-DXd in previously treated patients with advanced/metastatic NSCLC.
Aaron Lisberg Previously Treated Metastatic Non Small Cell Lung Cancer Randomized Phase Partnership With
Source: onclive.com
COMING SOON: EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Terence Friedlander, MD, shares a look at an upcoming program reviewing recent, significant data from the EV-302/KEYNOTE-A39 study.
Enfortumab Vedotin Randomized Phase Previously Untreated Locally Advanced Metastatic Urothelial Urothelial Carcinoma Urothelial Cancer
Source: onclive.com
COMING SOON: Randomized Phase 3 Study of First-Line Selpercatinib Versus Pembrolizumab and Chemotherapy in RET Fusion-Positive Non-Small Cell Lung Cancer
Expert oncologist Benjamin P. Levy, MD, shares his excitement for an upcoming program centered on recent data with selpercatinib versus pembrolizumab in patients with non-small cell lung cancer following ESMO 2023.
Randomized Phase First Line Selpercatinib Versus Pembrolizumab Positive Non Small Cell Lung Cancer Non Small Cell Lung Cancer Lung Cancer Ret Fusion
Source: onclive.com
COMING SOON: Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy for Patients with Metastatic HR+/HER2– BC: Primary Results from the Randomized Phase III TROPION-Breast01 Trial
Expert oncologist Aditya Bardia, MD, shares his excitement for an upcoming program centered on data from the TROPION-Breast01 trial of dato-DXd versus chemotherapy in metastatic HR+/HER2– breast cancer following ESMO 2023.
Datopotamab Deruxtecan Primary Results Randomized Phase Breast Cancer Metastatic Breast Cancer Hr Breast Cancer
Source: onclive.com
Clinical Overview: Comparison of Anti-Amyloid Monoclonal Antibodies for Alzheimer Disease
Aducanumab, lecanemab, and donanemab are novel monoclonal antibodies designed to slow disease progression and hopefully have a positive impact in the field of Alzheimer disease management.
Source: pharmacytimes.com
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
– Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be Presented in Late-Breaking Oral Presentation – SAN FRANCISCO, Oct. 2, 2023 /PRNewswire/ --...
Source: marketscreener.com